Key result
Increased platelet size and reticulated platelet content were associated with increased platelet activity and reduced efficacy of antiplatelet therapy in patients with CHD and ACS.
Why the study?
Increased platelet activity is a risk factor for thrombotic events, prompting study of the relationship between platelet function, size, and reticulated platelet content in patients on dual antiplatelet therapy.
Does dual antiplatelet therapy alter the relationship between platelet size, reticulated platelet content, and platelet activity in patients with CHD or ACS?
Observational (n=216)
Does dual antiplatelet therapy alter the relationship between platelet size, reticulated platelet content, and platelet activity in patients with CHD or ACS?
Increased platelet size and reticulated platelet content are associated with higher platelet reactivity and reduced efficacy of dual antiplatelet therapy in patients with CHD and ACS.
Answers are grounded in this paper and cite their sources.
These platelet indices may help identify ACS patients at risk for antiplatelet failure; leaves.
Increased platelet activity is a risk factor of thrombotic events in cardiovascular patients. We studied the relationship between platelet function, platelet size, and the content of reticulated platelets (RP) in patients with coronary heart disease (CHD, n = 55) and acute coronary syndrome (ACS, n = 95) receiving acetylsalicylic acid + clopidogrel or ticagrelor, respectively. The control group consisted of patients with risk factors for CHD, but with no CHD/ACS and free of antiplatelet drugs (n = 66). Platelet function was evaluated by the exposure of activated glycoprotein (GP) IIb-IIIa and P-selectin. In the control group, platelets were activated by TRAP (Thrombin Receptor Activating Peptide) 10 µM, and ADP 20, 5, 2.5 µM, and in the CHD/ACS groups, by TRAP 10 µM, and ADP 20 5 µM (±epinephrine 20 µM). Platelet size was assessed by the mean volume, % large forms, and forward scattering. RP were stained by thiazole orange. In the control group, activated GP IIb-IIIa and P-selectin correlated with platelet size and RP content after platelet activation by all agonists. Despite the decrease in platelet activity by antiplatelet drugs, most correlations (primarily for activated GP IIb-IIIa) were preserved in the CHD/ACS patients. In conclusion, increased platelet size and RP content are associated with increased platelet activity and the reduced efficacy of antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Bodrova et al. (2024) conducted an observational in Coronary heart disease and acute coronary syndrome (n=216). Dual antiplatelet therapy (ASA + clopidogrel or ticagrelor) vs. No antiplatelet drugs was evaluated on Correlation between platelet function (activated GP IIb-IIIa and P-selectin), platelet size, and reticulated platelets content. Increased platelet size and reticulated platelet content were associated with increased platelet activity and reduced efficacy of antiplatelet therapy in patients with CHD and ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: